Clinical Updatessystemic lupus erythematosusimmunotherapy
Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies
By MedXY|Sep 22, 2026
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.